Latest News for INCPF
InnoCare Pharma Limited (INCPF) Q2 2026 Earnings Call Transcript
China-based Innocare Pharma said on Monday the Phase III trial of fadeucravacitinib, an experimental treatment for moderate-to-severe plaque psoriasis, has met its primary endpoint.
BEIJING, July 05, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the clinical trial of novel CDH17 targeted ADC, ICP-B208, in China. Developed from InnoCare's in-house ADC platform, ICP-B208 is a novel ADC comprising a humanized anti-CDH17…
BEIJING, June 05, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that study results of its novel BTK inhibitor orelabrutinib in Phase IIb Study for systemic lupus erythematosus (SLE) were presented at the EULAR 2026 European Congress of Rheumatology in London. The Phase IIb clinical…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for INCPF.
Senate Trading
No Senate trades found for INCPF.
U.S. House Trading
No House trades found for INCPF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.